Triple-negative breast cancer (TNBC) exhibits the highest mortality rate among breast cancer subtypes due to its heterogeneity, aggressiveness, and poor differentiation compared to hormone receptor-positive (HR+) and HER2+ tumors, resulting in a lack of standardized treatment regimens [1]. This evidence concerns the gene ERBB2 and breast carcinoma.